Genentech, Inc.
NEWS
With more than 82,500 employees working in the sector, California’s Bay Area is one of the strongest homes for biotech companies in the world.
Seattle-based Adaptive Biotechnologies forged a collaboration with Genentech that could be worth up to $2 billion to develop and commercialize novel neoantigen directed T-cell therapies for the individualized treatment of a broad range of cancers.
Traditionally, Genentech has tended to operate with less hands-on scrutiny from the business bean counters at its Swiss Roche headquarters. These more recent job cuts suggest those days may be over.
Proteostasis Therapeutics, based in Boston, signed a worldwide, exclusive license deal with Genentech for rights to a possible small molecule modulator within the proteostasis network.
As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.
Late Thursday, Genentech said the U.S. Food and Drug Administration granted regulatory approval for a combination of Tecentriq and Avastin for treatment of some metastatic non-squamous non-small cell lung cancer (NSCLC) patients.
Roche subsidiary Genentech snaps up Jecure and its portfolio of preclinical NLRP3 inhibitors aimed at serious inflammatory diseases.
This deal is an expansion of an existing discovery collaboration. Immunocore will head the first-in-human clinical trial of the drug alone and in combination with Genentech’s checkpoint inhibitor Tecentriq (atezolizumab).
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
JOBS
IN THE PRESS